TGFβ pathway abrogation in CRC can occur through mutation of either TGFβ‐receptor 1 (TGFBR1) or TGFBR2. Furthermore, TGFβ pathway inactivation can occur via loss of heterozygosity (LOH) of chromosome 18q, where SMAD2 and SMAD4, two downstream mediators of TGFβ signalling, are located. The gene discussed is TGFBR2; the disease is colorectal carcinoma.